We’re Redefining Success in the ‘War on Cancer.’
At NanoValent Pharmaceuticals we’re advancing a new generation of targeted, novel format conjugates called nano-ADC like Targeted Nanospheres (nADC/TNS). These novel therapies incorporate our proprietary highly optimized Hybrid Polymerized Liposomal Nanoparticle (HPLN-) technology.
By repositioning existing therapies and truly targeting and optimizing the delivery of emerging candidates our nADC/TNS provide a vast improvement over current treatment options, resulting in an increase in therapeutic potency without increasing toxicities.
Our Executive Leadership
Get to know the talented individuals behind our agency
Jon Nagy, PhD
Chief Scientific Officer/President
Dr. Nagy is co-founder of NanoValent and received his PhD in synthetic organic chemistry from Iowa State University in 1983, and completed doctoral training at UC Berkeley. In 1990, Dr. Nagy joined Lawrence Berkeley National Laboratory, where he filed numerous key patents and published many scientific papers, including a paper in Science on polymer films and nanoparticles. In 1999, Dr. Nagy joined LigoCyte Pharmaceuticals as Director of Chemistry and Nanoparticle Research. He is now a full-time member of NanoValent.
Timothy Triche MD, PhD
Chief Medical Officer
Dr. Triche is co-founder of NanoValent and is board-certified in pathology and Co-Director for the Children’s Hospital Los Angeles (CHLA) Center for Personalized Medicine, as well as a tenured faculty member at the University of Southern California—his expertise centers on the field of tumor cell biology. Dr. Triche has been a principal and founder in several publicly traded companies.
Mark Lewis
Chief Executive Officer
Mr. Lewis has extensive international experience in the pharmaceutical industry; both as an executive with companies including Amersham International (now part of GE), Farmitalia (now Pfizer), Chiron (now Novartis), Groupe Servier, Ascalon and SuperGen (now Otsuka) in various senior commercial and operational roles and as a management and project consultant (including Quintiles, Hill & Knowlton) for a broad spectrum of pharmaceutical and biotechnology clients. With an honors degree in biochemistry and secondary business qualifications, Mr. Lewis has broad skills in strategic marketing, project management, business development, medical affairs and operations management gained in several therapeutic areas but primarily oncology